Back to News
Jan 12, 2026 12:10 PM

Pfizer Cancer Combo Drug Shows Strong Tumor Shrinkage in Colorectal Cancer Trial

On Saturday, Pfizer Inc. (NYSE:PFE) shared data from Cohort 3 of the BREAKWATER trial.

The Phase 3 BREAKWATER trial evaluated Braftovi (encorafenib) with cetuximab, alone or in combination with chemotherapy (mFOLFOX6 or FOLFIRI) for untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC).

Trial Data

At the time of this analysis, the Braftovi combination regimen with FOLFIRI and cetuximab demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response rate (ORR) compared to patients receiving standard-of-care treatment FOLFIRI with or without bevacizumab (64.4% vs 39.2%, odds ratio =2.76, p=0.001).

A confirmed ORR in cancer trials is the percentage of patients whose tumors shrink, and that response is verified ...